The ASIA PACIFIC LANCET AND PEN NEEDLES market is experiencing significant trends driven by the increasing prevalence of diabetes, advancements in diabetes management technologies, and a growing focus on patient-friendly solutions. These trends reflect the evolving landscape of lancet and pen needle products catering to the diverse needs of individuals managing diabetes across the Asia Pacific region.
According to the main factor influencing market trends is the rise in the rates of diabetes inflict in the Asia Pacific region. They ensure an effective brushed surface 100% of the time which, with the rising diabetic populace, is crucial for the appropriate administration of diabetes wherever in the world.
Lancets and pen needles are products of the continuous improvements in technology which are on the rise moulding their design and functionality. Used innovations include needles with a finer gauge to make injections less painful, ergonomic forms for better handling, needle shields and safety mechanisms to provide enhanced protection and convenience to users.
As the market has been observing a good trend towards shorter and disposable pen needles. Disposable pen needles provide convenience, whereby the manual needle changes are eliminated, significantly reducing the risk of contamination. The trend from ‘reuse’ to more disposable options on the one hand responds to the demand for convenient but also hygienic diabetes management.
The Asia Pacific region market for safety pen needles emerges on the rise. Insulin needles take account of shield or retraction solutions to lower the danger of unintentional needlestick wounds and encourage safer guidance of insulin, an imperative point of interest both for the dominated demonstrator and the beneficiary.
Increasingly, adjustable pen needle lengths are prevalent. However, these pen needles enable customization of the injection depth depending on users’ personal preferences and tolerances of pain. Delivering the level of patient-centricity to insulin delivery using flexible needle lengths.
Lancets and pen needles are more pediatric friendly also the pattern is becoming more. The needs of pediatric patient base managing diabetes with the help of insulin devices have been addressed by manufacturers developing products with needle gauges and lengths more suitable to children. Young users are less ‘intimidated’ with such insulin devices.
Needle-free technologies are becoming a new trend produced in the market of Asia Pacific. Injections are revolutionised provided without needles through mechanisms such as air pressure or electromagnetic forces for alternatives to individuals who might have needle-related fears or sensitivities.
This has triggered patient education and training initiatives. DIAsp Course Stadt proposes a series of activities targeting different target groups, focusing on the provision of educational materials, easy-to-read instructions, and training programs that empower users with diabetes to use lancets and pen needles properly, with correct technique, and stick to their insulin regimen.
Lancets and pen needles are gradually available as generic and affordable lancets and pen needles in the Asian-Pacific market. The aforementioned’ trend speaks to the demand of cost effective diabetes management options, hence making these life essential devices more affordable for larger population and fitting into the pinnacles of healthcare budget considerations.
Stringent regulatory frameworks and standardization efforts play a crucial role in shaping market trends. Compliance with international standards and regulatory approvals are becoming increasingly important for manufacturers to gain market acceptance and ensure the safety and quality of lancets and pen needles.
Intended Audience
The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.
On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.
On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.
On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.
Some of the key players in the Asia Pacific lancet and pen needles market are:
February 2024: Eli Lilly hopes to launch its bestselling antidiabetic medication, specified as Mounjaro (tripeptide), which will be around early next year. Indian health regulatory bodies, including Mounjaro, are currently investigating this.
June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), was granted marketing authorization for its Adalimumab injection in prefilled syringe (PFS). It is a biosimilar for high concentration adalimumab formulation for rheumatoid arthritis treatment.
During CPHI Japan 2023, SHL Medical introduced Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT).
September 2022: The Microsoft and Novo Nordisk partnership was announced in September 2022, merging computational services, cloud computing AI and knowledge thirst in drug development as well as Novo Nordisk’s data engineering services.
On September 2022, Novo Nordisk acquired Forma Therapeutics. That company is committed to changing lives of Sickle cell disease (SCD) patients among other rare blood diseases.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)